1. Home
  2. PODD vs CG Comparison

PODD vs CG Comparison

Compare PODD & CG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PODD
  • CG
  • Stock Information
  • Founded
  • PODD 2000
  • CG 1987
  • Country
  • PODD United States
  • CG United States
  • Employees
  • PODD N/A
  • CG N/A
  • Industry
  • PODD Medical/Dental Instruments
  • CG Investment Managers
  • Sector
  • PODD Health Care
  • CG Finance
  • Exchange
  • PODD Nasdaq
  • CG Nasdaq
  • Market Cap
  • PODD 21.5B
  • CG 22.9B
  • IPO Year
  • PODD 2007
  • CG 2012
  • Fundamental
  • Price
  • PODD $331.83
  • CG $64.87
  • Analyst Decision
  • PODD Strong Buy
  • CG Buy
  • Analyst Count
  • PODD 18
  • CG 16
  • Target Price
  • PODD $332.22
  • CG $57.14
  • AVG Volume (30 Days)
  • PODD 697.4K
  • CG 2.9M
  • Earning Date
  • PODD 08-07-2025
  • CG 08-06-2025
  • Dividend Yield
  • PODD N/A
  • CG 2.16%
  • EPS Growth
  • PODD N/A
  • CG N/A
  • EPS
  • PODD 3.32
  • CG 3.42
  • Revenue
  • PODD $2,359,500,000.00
  • CG $5,525,600,000.00
  • Revenue This Year
  • PODD $24.54
  • CG N/A
  • Revenue Next Year
  • PODD $17.48
  • CG $21.42
  • P/E Ratio
  • PODD $99.86
  • CG $18.96
  • Revenue Growth
  • PODD 26.00
  • CG 99.03
  • 52 Week Low
  • PODD $180.31
  • CG $33.02
  • 52 Week High
  • PODD $334.18
  • CG $65.97
  • Technical
  • Relative Strength Index (RSI)
  • PODD 68.39
  • CG 61.19
  • Support Level
  • PODD $327.17
  • CG $60.46
  • Resistance Level
  • PODD $334.18
  • CG $65.36
  • Average True Range (ATR)
  • PODD 8.48
  • CG 1.77
  • MACD
  • PODD 2.55
  • CG -0.23
  • Stochastic Oscillator
  • PODD 95.05
  • CG 80.04

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.

About CG The Carlyle Group Inc.

Carlyle Group is one of the world's largest alternative-asset managers, with $453 billion in total AUM, including $314 billion in fee-earning AUM, at the end of March 2025. The company has three core business segments: global private equity, which includes its private equity, real estate, infrastructure, and natural resources offerings (with $164 billion in total AUM and $99 billion in fee-earning AUM), global credit ($199 billion/$161 billion), and investment/fund solutions, known as Carlyle AlphInvest ($89 billion/$54 billion). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving more than 3,100 active carry fund investors from 87 countries.

Share on Social Networks: